Natus Medical (NASDAQ:BABY) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.12-1.49 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.64. The company issued revenue guidance of $490-510 million, compared to the consensus revenue estimate of $528.15 million.Natus Medical also updated its FY 2019 guidance to $1.12-1.49 EPS.
A number of research firms have issued reports on BABY. Zacks Investment Research cut Natus Medical from a hold rating to a strong sell rating in a report on Friday, October 26th. Roth Capital set a $36.00 target price on Natus Medical and gave the stock a buy rating in a report on Thursday, October 25th. BidaskClub upgraded Natus Medical from a hold rating to a buy rating in a report on Wednesday, November 21st. Finally, ValuEngine upgraded Natus Medical from a hold rating to a buy rating in a report on Thursday, December 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $36.00.
Shares of NASDAQ BABY traded down $3.64 during mid-day trading on Wednesday, hitting $26.23. The company had a trading volume of 114,308 shares, compared to its average volume of 429,990. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 18.12 and a beta of 0.58. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.62 and a quick ratio of 1.89. Natus Medical has a one year low of $27.69 and a one year high of $37.95.
In other news, Director Ken Ludlum sold 30,000 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $31.02, for a total value of $930,600.00. Following the completion of the transaction, the director now owns 73,957 shares in the company, valued at approximately $2,294,146.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert A. Gunst sold 14,750 shares of the firm’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $33.54, for a total value of $494,715.00. Following the completion of the transaction, the director now owns 32,392 shares of the company’s stock, valued at approximately $1,086,427.68. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2019/02/13/natus-medical-baby-updates-fy19-earnings-guidance.html.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Read More: What is cost of equity?
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.